3 of 6
BACK NEXT
Gilead Sciences
Gilead Sciences
Est. quarterly earnings growth: 14%
Est. full-year earnings growth: 19%

The second-largest biotech in terms of market value, Gilead Sciences has cornered the market for HIV medications. With 85% of its revenues coming from AIDS-related drugs in addition to an excellent product lineup, Gilead is well positioned to produce strong results in the current quarter and in the future.

"Gilead is the best of breed because it is immune to economic fluctuations," said Richard Russell, chief investment officer of Ariston Capital Management, who manages a fund with Gilead as its top holding. "If you have HIV, you're going to take a Gilead drug."

Gilead also receives royalty revenue from the lucrative Tamiflu drug. Gilead developed Tamiflu and licenses it to Swiss drug maker Roche. Gilead is expected to report a profit of 48 cents a share in the second quarter, up from 42 cents a year ago.

"With what can be described as a slow economy at best, we're in a stock market that will value long-term growth," said Russell. And it's hard to find better growth than Gilead, whose profits are expected to increase nearly 24% per year over the next five years.

NEXT: Hess Corp.
Last updated June 20 2008: 12:23 PM ET
More Galleries
10 of the most luxurious airline amenity kits When it comes to in-flight pampering, the amenity kits offered by these 10 airlines are the ultimate in luxury More
7 startups that want to improve your mental health From a text therapy platform to apps that push you reminders to breathe, these self-care startups offer help on a daily basis or in times of need. More
5 radical technologies that will change how you get to work From Uber's flying cars to the Hyperloop, these are some of the neatest transportation concepts in the works today. More

Special Offer

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2018 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc. 2018. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2018 and/or its affiliates.